comparemela.com

Latest Breaking News On - Candice sehoma - Page 3 : comparemela.com

Fight against U S pharmaceutical giant hots up

Fight against U S pharmaceutical giant hots up
health-e.org.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from health-e.org.za Daily Mail and Mail on Sunday newspapers.

SA advocacy groups take on big pharma for access to R5m-a-year cystic fibrosis drug

The Treatment Action Campaign and Doctors Without Borders Southern Africa are fighting for easier access to a cystic fibrosis drug that costs a steep R5 million per patient, per year.

IOL | News that Connects South Africans

IOL | News that Connects South Africans
iol.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iol.co.za Daily Mail and Mail on Sunday newspapers.

TAC and MSF intervene in a case for a lifesaving cystic fibrosis drug priced at over R5 million

In what could be a groundbreaking case for affordable access to medicines in South Africa, the Treatment Action Campaign (TAC) and Doctors Without Borders (MSF) Southern Africa, both represented by SECTION27, have filed papers in the Pretoria High Court to intervene as amici curiae (friends of the court) in a compulsory license application for access to a lifesaving drug to treat cystic fibrosis, called Trikafta. Cystic fibrosis is a severe multisystem illness that can cause frequent serious lung infections, including antimicrobial-resistant bacteria, liver and pancreatic damage, lung failure, and can even necessitate lung transplant.

OPINION | TRIPS non-waiver outcome highlights need for domestic intellectual property law reform

The disappointing WTO outcome increases the urgency for domestic intellectual property law reform in the interests of public health and the realisation of people's constitutional right to access healthcare services, write Candice Sehoma and Baone Twala.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.